Vasopressin in vasodilatory shock: is the heart in danger?

Crit Care. 2008;12(2):132. doi: 10.1186/cc6839. Epub 2008 Apr 10.

Abstract

In patients with hyperdynamic hemodynamics, infusing arginine vasopressin (AVP) in advanced vasodilatory shock is usually accompanied by a decrease in cardiac output and in visceral organ blood flow. Depending on the infusion rate, this vasoconstriction also reduces coronary blood flow despite an increased coronary perfusion pressure. In a porcine model of transitory myocardial ischemia-induced left ventricular dysfunction, Müller and colleagues now report that the AVP-related coronary vaso-constriction may impede diastolic relaxation while systolic contraction remains unaffected. Although any AVP-induced myocardial ischemia undoubtedly is a crucial safety issue, these findings need to be discussed in the context of the model design, the dosing of AVP as well as the complex direct, afterload-independent and systemic, vasoconstriction-related effects on the heart.

Publication types

  • Comment

MeSH terms

  • Animals
  • Arginine Vasopressin / pharmacology*
  • Brain / blood supply*
  • Cardiac Output / drug effects*
  • Coronary Circulation / drug effects*
  • Kidney / blood supply*
  • Male
  • Muscle, Smooth, Vascular / drug effects*
  • Myocardial Ischemia / drug therapy
  • Myocardial Reperfusion
  • Swine
  • Vasoconstrictor Agents / pharmacology*

Substances

  • Vasoconstrictor Agents
  • Arginine Vasopressin